ALLR
Allarity Therapeutics, Inc. (ALLR) SWOT Analysis Analysis (2026)
No material changes this month.
Strengths
Liquidity ratios near 1.1 indicate limited but usable near-term coverage, which is better than distressed peers with sub-1.0 current liquidity.
Negative net debt to EBITDA suggests EBITDA is not the binding constraint, but this is less meaningful than peers with positive, recurring operating cash generation.
Weaknesses
ROIC of -41.8% shows capital is being destroyed, leaving ALLR structurally behind peers that at least preserve invested capital.
Debt to equity of 6.3x indicates heavy leverage relative to equity, which amplifies financing risk versus less levered peers.
Cash conversion cycle of 59,126 days signals extreme working-capital inefficiency, far worse than peers and directly constraining liquidity and reinvestment.
Missing margin data alongside negative returns suggests the business lacks visible operating leverage, unlike peers with measurable gross and operating margin support.
Opportunities
If ALLR can normalize working capital, the current liquidity base could support a turnaround more effectively than peers already operating at tighter cash buffers.
Any improvement in capital efficiency would have outsized impact because the current ROIC deficit leaves substantial room to close the gap with peers.
Threats
Persistent negative ROIC increases the risk that peers with positive returns will compound faster and widen the structural gap in market positioning.
High leverage relative to equity leaves ALLR more exposed than peers to refinancing pressure, especially if operating performance remains weak.
The extreme cash conversion cycle raises the probability of ongoing liquidity strain, which can force dilution or asset sales before peers face similar pressure.
Overall Score
ALLR is structurally weak versus peers because negative capital returns, high leverage, and severe working-capital inefficiency outweigh its limited near-term liquidity.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Allarity Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.
